Tesis sobre el tema "Advanced therapy medicine"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte los 34 mejores tesis para su investigación sobre el tema "Advanced therapy medicine".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Explore tesis sobre una amplia variedad de disciplinas y organice su bibliografía correctamente.
VIGANI, BARBARA. "Development of Advanced Therapy Medicinal Products for Regenerative Medicine". Doctoral thesis, Università degli studi di Pavia, 2017. http://hdl.handle.net/11571/1203351.
Texto completoCoward, Jermaine. "The effects of anti-IL-6 therapy in advanced ovarian cancer". Thesis, Queen Mary, University of London, 2010. http://qmro.qmul.ac.uk/xmlui/handle/123456789/457.
Texto completoFall, Per-Arne. "Aspects of Parkinson's disease. Epidemiology, risk factors and ECT in advanced disease". Doctoral thesis, Linköpings universitet, Geriatrik, 1999. http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-5011.
Texto completoOn the day of the public defence the status of the article IV was: Submitted; articel V was: Accepted for publication after revision.
水野, 正明, 純. 吉田, Masaaki Masaaki Mizuno y Jun Yoshida. "悪性グリオーマに対する遺伝子治療". 日本脳神経外科コングレス, 2006. http://hdl.handle.net/2237/10865.
Texto completoGonzalez, Gomez Mayte Lorena. "Methylglyoxal Effects in Cell Therapy for Myocardial Infarction". Thesis, Université d'Ottawa / University of Ottawa, 2018. http://hdl.handle.net/10393/38431.
Texto completoBalbadhur, Raksha. "Understanding the dignity experience and exploring the impact of dignity therapy and guided imagery on patients with advanced disease - a South African perspective". Master's thesis, University of Cape Town, 2017. http://hdl.handle.net/11427/24874.
Texto completoHasfal, Sharon hasfal. "Development of a Scholarly Educational Intervention to Improve Inpatient Diabetes Care". ScholarWorks, 2018. https://scholarworks.waldenu.edu/dissertations/5086.
Texto completoFornaguera, Puigvert Cristina. "Development of multifunctional polymeric nanoparticles by nano-emulsion templating as advanced nanocarriers targeting the blood-brain barrier". Doctoral thesis, Universitat de Barcelona, 2015. http://hdl.handle.net/10803/285368.
Texto completoLes nanopartícules polimèriques multifuncionals (NPs) representen una alternativa prometedora pel tractament de malalties neurodegeneratives, a través de l’administració intravenosa (i.v.), ja que els tractaments actuals provoquen molts efectes secundaris. Les NPs, en canvi, si estan correctament dissenyades, poden actuar específicament en el teixit diana. Ja que l’òrgan diana és el cervell, és necessari un element de vectorització per poder creuar la barrera hemato-encefàlica (BBB). En aquest context, l’objectiu de la present tesi és l’obtenció de NPs com a sistemes avançats d’alliberament de principis actius que travessin la BBB. Es van obtenir NPs a partir de nano-emulsions (NE) plantilla, emprant l’àcid poli-(làctic-co-glicòlic) com a polímer i el mètode d’inversió de fases a temperatura constant per emulsionar, seguit d’evaporació de solvent per obtenir NPs. Les NPs obtingudes tenen mides apropiades per l’administració i.v.. Es va aconseguir encapsular un fluorescent i NPs magnètiques dins les NPs polimèriques, per fer-les servir com a sistemes d’imatge. També es van encapsular fàrmacs per usar-les com a sistemes terapèutics. En tots els casos, es van aconseguir eficiències d’encapsulació molt elevades i un alliberament del fàrmac controlat i prolongat en el temps. A més, es va aconseguir funcionalitzar la superfície de les NPs amb diferents elements. Es van unir covalentment dendrons catiònics per posteriorment unir oligonucleòtids electrostàticament. També es va afegir una coberta exterior de polietilenglicol per protegir el material genètic. Per altra banda, es va funcionalitzar la superfície de les NPs amb un anticòs específic contra el receptor de la transferrina, sobreexpressat a la BBB. A continuació, es van fer assajos in vitro, que van posar de manifest que les NPs no són citotòxiques ni hemolítiques. També es va estudiar l’eficiència de transfecció cel•lular del material genètic, arribant a eficiències de transfecció equivalents a les dels vectors comercials. Assajos in vivo van permetre confirmar el pas a través de la BBB, sobretot de les NPs funcionalitzades amb l’anticòs. Els resultats obtinguts permeten concloure que s’ha aconseguit dissenyar noves NPs polimèriques a partir de NE, apropiades per l’administració i.v. i amb capacitat de travessar la BBB.
Daum, Ruben [Verfasser]. "Development and Non-invasive Quality Assessment of Advanced Therapy Medicinal Products / Ruben Daum". Tübingen : Universitätsbibliothek Tübingen, 2021. http://d-nb.info/1232725773/34.
Texto completoAbou, El-Enein Mohamed [Verfasser]. "The economics of manufacturing clinical-grade advanced therapy medicinal products (ATMPs) / Mohamed Abou El-Enein". Berlin : Medizinische Fakultät Charité - Universitätsmedizin Berlin, 2014. http://d-nb.info/1046832859/34.
Texto completoSmart, Susanna Jennifer. "Grounded Theory of Rosen Method Bodywork". Kent State University / OhioLINK, 2018. http://rave.ohiolink.edu/etdc/view?acc_num=kent1524757138389208.
Texto completoZscharnack, Matthias, Christoph Krause, Gabriela Aust, Christian Thümmler, Frank Peinemann, Thomas Keller, Jeske J. Smink et al. "Preclinical good laboratory practice-compliant safety study to evaluate biodistribution and tumorigenicity of a cartilage advanced therapy medicinal product (ATMP)". Universitätsbibliothek Leipzig, 2015. http://nbn-resolving.de/urn:nbn:de:bsz:15-qucosa-170184.
Texto completoSerhal, Nada. "Analyse du potentiel pro-angiogénique de vésicules extracellulaires libérées par des cellules souches mésenchymateuses, en vue de leur utilisation dans le traitement de l'artériopathie oblitérante des membres inférieurs". Electronic Thesis or Diss., Reims, 2024. http://www.theses.fr/2024REIMS007.
Texto completoMesenchymal stromal cells (MSCs) show promising angiogenic potential for the treatment of ischemic arterial diseases, particularly in peripheral arterial disease. The small extracellular vesicles (sEVs) produced by these cells may have comparable potential. Indeed, sEVs act as cargo, transporting biological materials to transfer to host cells in the sites of ischemia. This study focuses on the characterization of undifferentiated MSCs and endothelial-like MSCs cultured under hypoxic conditions (MSC-ELH) and their sEVs. MSC-ELH are characterized by the overexpression of key endothelial mRNAs; they can produce large amount of sEVs, pro-angiogenic and mitogenic factors, and a small quantity of IL-6, a cytokine that is deleterious in the context of tissue ischemia. MSC-ELH-derived sEVs are endowed with high pro-angiogenic potential as they contain the mRNAs coding for VEGF-A, FGF2, EGF and corresponding proteins. sEVs can internalize in endothelial cells and skeletal muscle cells. MSCs-EVs can deliver their content to target cells and stimulate their proliferation and pseudo-tube formation, in an in vitro assay. This work highlights the beneficial impact of hypoxia and endothelial differentiation on MSC-ELH. Derived sEVs, may be used as therapeutic vectors for the treatment of ischemic arterial disease, as an innovative "cell-free" therapy
ANDRENELLI, ELISA. "Advanced technologies enhance exercise effectiveness in neurodegenerative disorders: evidence from neuroplasticity studies". Doctoral thesis, Università Politecnica delle Marche, 2019. http://hdl.handle.net/11566/263447.
Texto completoNeurodegenerative diseases such as Parkinson’s disease and multiple sclerosis are characterised by the appearance of reactive microglial and astroglial cells, a process referred to as neuroinflammation. Activation of glia cells can induce an increase in the levels of pro- and antiinflammatory cytokines and reactive oxygen species, which can lead to the modulation of neuronal function and neurotoxicity observed in several brain pathologies. There is no conclusive evidence that can classify the inflammation as a cause or a consequence of the disease onset. However, therapeutic approaches specifically targeting neuroinflammation and neuroplasticity may represent an effective strategy to interfere with the disease progression and consequently for preventing or treating the related symptoms. Exercise is known to effectively modulate inflammation and has been reported to change the inflammatory state to become anti-inflammatory or neuroprotective. Moreover, exercise increases synaptic plasticity by directly affecting synaptic structure and potentiating synaptic strength, and indirectly by strengthening the underlying systems that support plasticity including neurogenesis, metabolism and vascular function. More studies are needed to elucidate the likely range of intensity, duration, frequency, and type (aerobic or task oriented) of exercise that is required to induce such important target responses. In the following studies we showed how specific gait training could improve symptoms that are unresponsive or that poorly respond to pharmacological treatment in two common neurodegenerative disorders, Parkinson's disease and multiple sclerosis. At baseline assessment, all patients enrolled, either suffering from Parkinson's disease or multiple sclerosis, showed an impaired neuroplasticity that recovered only after robot gait training. This neurophysiological result was correlated to clinical improvement of the freezing of gait in Parkinson's disease and gait and balance in multiple sclerosis.
Magalon, Jérémy. "Développement d'un médicament de thérapie innovante utilisant la fraction vasculaire stromale du tissu adipeux autologue dans la sclérodermie systémique : de la caractérisation biologique à l'identification de biomarqueurs potentiels d'efficacité". Thesis, Aix-Marseille, 2018. http://www.theses.fr/2018AIXM0048.
Texto completoThe aim of this work is to characterize the antifibrotic and angiogenic effects of FVS and to evaluate the impact of the scleroderma context on these angiogenic properties. On the other hand, to identify a strategy of biological monitoring of this therapy applicable to the sclerodermic context.The first step was to determine whether locally injected FVS can limit fibrosis in vivo. The injection of SVF performed early or late is accompanied by a significant reduction in the area of fibrosis in favor of muscle surfaces in a porcine model of urinary incontinence. The second component was to investigate whether the autologous context of systemic scleroderma affects the angiogenic properties of SVF. This study showed a slight alteration of angiogenic capacity on in vivo Matrigel Plug assays associated with a transcriptomic signature of SVF of scleroderma patients. The third component was to identify a biological monitoring strategy that could be used to objectively evaluate the impact of new therapies on vasculopathy associated with systemic sclerosis. The elevation of EPCs and Fractalkine independently predict the severity score of the disease and the severity of pulmonary fibrosis.This work has made it possible to progress in the development of an innovative cell therapy to limit the ischemic vasculopathy and the fibrosis causing hand handicap in scleroderma patients and to monitor its effectiveness in the future
Trigueros, Angelique Francesca. "Using Parent-Identified Strengths of Autistic Children to Advance Strength-Based Intervention". ScholarWorks, 2018. https://scholarworks.waldenu.edu/dissertations/5803.
Texto completoMoisan, Anaïck. "Mécanismes d'action de la thérapie cellulaire par cellules souches mésenchymateuses après infarctus cérébral chez le rat. Développement d'un médicament de thérapie innovante". Thesis, Grenoble, 2012. http://www.theses.fr/2012GRENS033/document.
Texto completoStroke is the leading cause of disability in adult. Less than 10% of patients can be treated with thrombolysis. Except rehabilitation, no effective treatment exists to improve functional recovery after the acute phase. Therefore, there is a wide need to develop an effective therapy applicable after several days or weeks following stroke. Using a multiparametric approach (microvascular MRI, analysis of angiogenic genes expression and behavioral study) in rat ischemic stroke model, we defined a transition stage (D3-D7) followed by a subacute phase (D7-D25) during post-stroke remodeling. These two phases represent an interesting target time-window for administration of pro-angiogenic therapies. Since 20 years, cell therapy, notably by human mesenchymal stem/stromal cells (hMSC), emerged as a “regenerative treatment” with threefold increase in clinical trial during the last 10 years. However, still limited data are available regarding the mechanisms by which hMSC benefit, especially at the subacute phase. We progressed in understanding the microvascular plasticity that occurs after an intravenous injection of hMSC in a rat model of transient focal cerebral ischemia. Our preclinical studies were carried out simultaneously with a phase II clinical trial that currently goes on in Grenoble (ISIS: Intravenous Stem Cells After Ischemic Stroke). We reported a sustained functional and cognitive long-term benefit of hMSC IV injected at the subacute stage correlated to an increase of angiogenesis. Ang2, Ang1, SDF-1 and TGFβ1, whose endogenous level tends to be overexpressed by hMSC, would enhance stabilization and survival of newborn vessels, accounting for benefit of these cells. As part of the hMSC development as an advanced therapy medicinal product, we realized an in vivo tumorigenicity assay and showed the absence of tumor development after hMSC injection. We also retrospectively analyzed hMSC produced for the phase II clinical trial. We confirmed the feasibility to produce hMSC, conformed to specifications and in adequate quantity, in the Cell Therapy Unit. In addition, we showed that ex vivo expanded hMSC can present, non clonal, erratic chromosomal abnormalities. Such chromosomal abnormalities appeared to be more related to the maintenance in culture than to the manufacturing process. A “donor” component may also contribute to emergence of such abnormalities
Avercenc-Léger, Léonore. "Devenir des propriétés immunomodulatrices des cellules souches mésenchymateuses de la gelée de Wharton au cours de la différenciation chondrocytaire". Thesis, Université de Lorraine, 2017. http://www.theses.fr/2017LORR0210/document.
Texto completoThe purpose of this work is to determine the optimal conditions for allogeneic substitutes production, adapted to filling the cartilaginous lesions in osteoarthritis treatment. It focuses on the cellular component of these substitutes. The use of mesenchymal stem cells from umbilical cords (WJ-MSC) involves determining which factors, related to direct and indirect environment of the WJ-MSC, can influence their proliferation and chondrogenic differentiation. In a first part of our work, three types of factors were studied: related to the donor child, the course of labor and delivery, pregnancy and the mother. Our results show that WJ-MSC have enhanced proliferative capacities when coming from full-term birth and without complications, with the use of Syntocinon® during labor. On this basis, we used the most effective WJ-MSC for cartilage engineering. It was then essential to elucidate their action profile in allogeneic context. We stimulated WJ-MSC embedded in Alginate/Hyaluronic Acid (Alg/HA) scaffolds with different concentrations of IFN-γ and TNF-α in order to determine the most effective stimulation profile, with regard to viability of the cells and evolution of immunomodulatory soluble factors secretion. According to our results, the stimulation by IFN-γ and TNF-α on WJ-MSC in Alg/HA scaffolds is more effective when these two cytokines are used together and is not deleterious for cell viability at the concentrations of 20 and 30 ng/mL, respectively. This double stimulation induces an increase in the secretion of IL-6 and PGE-2 by the WJ-MSC, a decrease in the secretion of VEGF and does not modify the secretion of TGF-β. We confirmed these data during a functional study: cocultures with peripheral blood mononuclear cells (PBMC) from healthy donors allowed us to evaluate the response of WJ-MSC in an allogeneic situation. These allogeneic situations have been studied at different times to evaluate the immunological properties of WJ-MSC during the time of chondrogenic differentiation. Our results show that WJ-MSC can express HLA-G molecules as well as IDO, but these expressions are limited in Alg/HA biomaterials. Finally, the WJ-MSC in Alg/HA biomaterials in allogeneic conditions are not immunogenic, regardless of the time of differentiation. On the other hand, their immunomodulatory capacities decrease over time and are stronger at day 0 and day 3 of chondrogenic differentiation, which leads to an early use of these cells. Finally, this work allows us to (i) select the umbilical cords suitable for cellular and cartilage engineering, (ii) define the conditions mimicking in vitro an allogeneic situation, (iii) elucidate the immunomodulatory properties of WJ-MSC during Alg/HA biomaterials chondrogenic differentiation, including allogeneic situations
Wagner, Quentin. "Optimisation de dispositifs médicaux thérapeutiques implantables pour l'ingénierie tissulaire osseuse et cartilagineuse". Thesis, Strasbourg, 2017. http://www.theses.fr/2017STRAJ114/document.
Texto completoOur team optimized the formulation of implantable medical devices for bone and cartilage tissue engineering. To that end, we based our work on nanostructured implants, either natural or synthetic, made in the laboratory by electrospinning process, to mimic bone extracellular matrix, and hydrogel of alginate/hyaluronic acid to mimic cartilage extracellular matrix. First, concerning bone regeneration, we optimized the formulation of a nanostructured scaffold composed of natural chitosan to enhance bone regeneration. This was made possible by doping this implantable medical device with silica nanoparticles, offering this nanocomposite better mechanical properties, and excellent biocompatibility with host tissue. Another study with the same aim allowed elaborating a new cell seeding strategy, to seed these implantable medical devices with cell microtissues instead of single cells, offering higher mineralisation efficiencies within the implant. Consequently, for the regeneration of the osteochondral unit, we proposed two compartmented and hybrid implants comprising mesenchymal stem cells microtissues. Those implants are made of a hydrogel containing the stem cells, allowing the regeneration of cartilage, and a membrane, either natural (collagenic Bio-Gide®) or synthetic (electrospun polycaprolactone) equipped with nanoreservoirs (technology patented by the laboratory) of osteogenic growth factor (BMP-7) for the regeneration of osseous stand (the subchondral bone) of the bone-cartilage unit. Finally, to study the improvement in vascular recruitment, we proposed a new strategy combining the modification of an implantable device with angiogenic growth factor (VEGF), prior to its sequential seeding with mesenchymal cells “human osteoblasts” and human endothelial cells (HUVECs). This strategy allowed higher recruitment and structuration of endothelial cells within the implant. To conclude, the implant optimisation strategies developed in the laboratory will certainly allow proposing in the near future new combined Advanced Therapy Medicinal Products (ATMPs) and Implantable Medical Device for bone and cartilage regeneration, in particular in the field of osteoarticular regenerative nanomedicine
Nieves, Christina Impoco. "Expressive Arts Intervention for the Adult Cancer Survivor in the Community Support Group Setting". Kent State University / OhioLINK, 2019. http://rave.ohiolink.edu/etdc/view?acc_num=kent1573897771394791.
Texto completoMcCune, Susana Lauraine. "Worlds of Connection: A Hermeneutic Formulation of the Interdisciplinary Relational Model of Care". Antioch University / OhioLINK, 2015. http://rave.ohiolink.edu/etdc/view?acc_num=antioch1404395833.
Texto completoPatout, Maxime. "Evaluation des techniques pour la prise en charge diagnostique et thérapeutique de l'insuffisance respiratoire chronique A Randomized controlled trial on the effect of needle gauge on the pain and anxiety experienced during radial arterial puncture Long term survival following initiation of home non-invasive ventilation : a European study Neural respiratory drive predicts long-term outcome following admission for exacerbation of COPD : a post hoc analysis Neural respiratory drive and cardiac function in patients with obesity hypoventilation syndrome following initiation of non-invasive ventilation Polysomnography versus limited respiratory monitoring and nurse-led titration to optimise non-invasive ventilation set-up a pilot randomised clinical trial Chronic ventilator service Step-down from non-invasive ventilation to continuous positive airway pressure : a better phenotyping is required AVAPS-AE versus ST mode : a randomized controlled trial in patients with obesity hypoventilation syndrome Technological advances in home non-invasive ventilation monitoring : reliability of data and effect on patient outcomes Efficacy of a home discharge care bundle after acute exacerbation of COPD Prediction of severe acute exacerbation using changes in breathing pattern of COPD patients on home noninvasive ventilation Charasteristics and outcome of patients set up on high-flow oxygen therapy at home Trial of portable continuous positive airway pressure for the management of tracheobronchomalacia". Thesis, Normandie, 2019. http://www.theses.fr/2019NORMR115.
Texto completoSingle-organ respiratory failure defines chronic respiratory failure. Obesity hypoventilation syndrome is the main cause of chronic respiratory failure and occurs in 4 to 5% of obese patients. Chronic respiratory failure is also the end-stage evolution of chronic obstructive pulmonary disease that has a prevalence of 6 to 8% in the adult population. The incidence of these diseases increases so does the incidence of chronic respiratory failure. In this thesis, we will evaluate novel diagnostic and therapeutic modalities that could improve the care of patients with chronic respiratory failure. Regarding diagnostic modalities, we have seen that evaluating the work of breathing with surface parasternal electromyography was an independent prognostic marker in patients with chronic obstructive pulmonary disease. We have also seen that it was a relevant tool to predict the clinicalefficacy and compliance to home non-invasive ventilation. Regarding therapeutic modalities, we have shown that the use of a semi-automatic mode of non-invasive ventilation had the same efficacy of a standard mode with a shorter length of stay for its setup. We have shown the relevance and feasibility of the use of high-flow oxygen therapy in the home setting whilst it was only used in intensive care units. Finally, we have shown the benefits of continuous positive airway pressure during exertion in patients with tracheobronchomalacia. Regarding patients’ follow-up, we have shown that the use of data from built-in software could predict the onset of a severe exacerbation of chronic obstructive pulmonary disease. However, we also show that the implementation of tele-medicine in patients with chronic respiratory failure cannot be included in daily clinical practice yet. In this thesis, we have identified novel physiological tools, novel ways to administer treatments and novel follow-up tools that can improve the management of patients with chronic respiratory failure
Pugliano, Marion. "Conception et optimisation d'un implant thérapeutique combiné à des organoïdes de cellules souches pour la nanomédecine régénérative ostéoarticulaire". Thesis, Strasbourg, 2019. http://www.theses.fr/2019STRAJ111.
Texto completoOur team has developed an innovative strategy based on biphasic therapeutic implants allowing a more effective and long-lasting regeneration of articular cartilage in the treatment of osteochondral lesions. These implants may represent better alternatives to the current treatments used in orthopaedic surgery. First, we developed a jellyfish type II collagen therapeutic implant model, functionalized with TGF-β3 growth factor nanoreservoirs, and equipped with human bone marrow-derived mesenchymal stem cells (hMSCs). The biocompatibility and chondrogenic properties of this implant have been validated in vitro, confirming its therapeutic potential for the regeneration of articular cartilage. In a second time, we focused more on the regeneration of the osteochondral unit. Indeed, it is crucial to regenerate a healthy subchondral bone, to allow a stable regeneration of articular cartilage on the surface. To this end, we have developed a therapeutic implant with two compartments : (i) a first compartment based on a synthetic poly-ε-caprolactone (PCL) biomaterial, equipped with BMP-7 growth factor nanoreservoirs, for the regeneration of the subchondral bone ; (ii) a second compartment based on a hydrogel of alginate and hyaluronic acid, seeded with hybrid organoids of hMSCs and human chondrocytes, for the regeneration of the articular cartilage. The effectiveness of this biphasic implant has been confirmed in vitro and in vivo in mice. Thirdly, we evaluated our biphasic therapeutic implant strategy in the large animal (sheep). This work validated the feasibility and effectiveness of our strategy, by combining : (i) a commercial collagen implant with BMP-2 growth factor nanoreservoirs, for the regeneration of the subchondral bone ; (ii) a hydrogel of alginate and hyaluronic acid, incorporating organoids of sheep bone marrow MSCs, for the regeneration of articular cartilage. In conclusion, these combined advanced medicinal products (ATMPs), combining natural or synthetic biomaterials (implantable medical device), therapeutic molecules and mesenchymal stem cells, allow the regeneration of the entire osteochondral unit. This innovative strategy will undoubtedly lead to major advances in osteoarticular regenerative nanomedicine, aiming to improve the treatment and comfort of patients
Lee, Yuan-Wen y 李元文. "Traditional Chinese Medicine as Adjunctive Therapy for Patients with Advanced Breast Cancer". Thesis, 2014. http://ndltd.ncl.edu.tw/handle/37gmmr.
Texto completo臺北醫學大學
藥學系(碩博士班)
102
Traditional Chinese medicine (TCM) is one of the most common complementary and alternative medicines employed in the treatment of breast cancer patients. However, the clinical evidences of TCM in large scale studies on survival, which is the major concern for breast cancer patients are still lacking. This study used the Taiwan National Health Insurance Research Database (NHIRD) to conduct a retrospective population-based cohort study of advanced breast cancer patients between 2001 and 2010. The patients were separated into TCM user and nonuser groups, and Cox regression models were applied to determine the association between the use of TCM and patient survival. In addition, this study investigated the effects on systemic infection, severe complications, analgesic usage, and health care utilization when using TCM in this specific population. Total of 729 advanced breast cancer patients receiving taxanes were included in this study, 115 TCM users and 614 TCM nonusers with the mean age of 52.0 years. The mean time of follow-up was 2.8 years, with 277 deaths during the 10-year period. Multivariate analysis demonstrated that, compared with nonusers, the use of TCM was associated with a significantly decreased risk of all-cause mortality (adjusted hazard ratio [HR], 0.55 [95% CI, 0.33–0.90] for TCM use for 30-180 days; adjusted HR, 0.46 [95% CI, 0.27–0.78] for use more than 180 days). Further analysis in 115 TCM users, the most frequent TCMs used by breast cancer patients were Jia Wei Xiao Yao San, Pu Gong Ying, and Bai Hua She She Cao. In addition, the results showed that the use of TCM would reduce systemic infection, analgesic usage, and the length of hospitalization for these cancer patients. Adjunctive TCM therapy with taxanes may lower the risk of death and systemic infection in advanced breast cancer patients. It could also reduce analgesic usage and the length of hospitalization among these patients. Future randomized controlled trials are still needed to validate these findings.
Garcia-Neuer, Marlene. "Systematic diagnostic evaluation for immune-related colitis: a single institutional review of advanced melanoma patients treated with ipilimumab". Thesis, 2016. https://hdl.handle.net/2144/17019.
Texto completo"A prospective longitudinal observational study on the effectiveness of Chinese herbal medicine in advanced cancer patients". 2010. http://library.cuhk.edu.hk/record=b5894361.
Texto completoThesis (M.Phil.)--Chinese University of Hong Kong, 2010.
Includes bibliographical references (leaves 177-189).
Abstracts in English and Chinese; includes Chinese.
Abstract --- p.i
摘要 --- p.iii
Acknowledgements --- p.v
Table of Contents --- p.vii
List of Appendices --- p.xi
List of Tables --- p.xii
List of Figures --- p.xiv
Abbreviations --- p.xvi
Chapter Chapter 1 --- Introduction --- p.1
Chapter 1.1 --- General Introduction --- p.1
Chapter 1.2 --- Background to the study --- p.2
Chapter 1.2.1 --- Epidemiology of cancer --- p.2
Chapter 1.2.1.1 --- Incidence and mortality in the World --- p.2
Chapter 1.2.1.2 --- Incidence and mortality in Hong Kong --- p.4
Chapter 1.2.2 --- Prevalence of Traditional Chinese Medicine (TCM) --- p.5
Chapter 1.2.3 --- Prevalence of Traditional Chinese Medicine (TCM) in cancer --- p.6
Chapter 1.2.4 --- Development of TCM in Hong Kong --- p.7
Chapter 1.3 --- Theoretical rationale of the study --- p.8
Chapter 1.4 --- Significance of the study --- p.11
Chapter Chapter 2 --- Literature Review --- p.13
Chapter 2.1 --- Introduction --- p.13
Chapter 2.2 --- The concept of Advanced Cancer --- p.13
Chapter 2.2.1 --- Pathology of Advanced Cancer --- p.14
Chapter 2.2.1.1 --- Metastatic Cancer --- p.14
Chapter 2.2.2 --- Sign and Symptoms of Advanced Cancer --- p.19
Chapter 2.2.3 --- Diagnosis of Advanced Cancer --- p.19
Chapter 2.2.4 --- Current Treatment for Advanced Cancer --- p.21
Chapter 2.2.5 --- Limitation of Current Treatments --- p.24
Chapter 2.3 --- Diagnosis and Treatment by TCM of Advanced Cancer --- p.26
Chapter 2.3.1 --- (Advanced) Cancer from the TCM perspectives --- p.26
Chapter 2.3.2 --- Diagnosis by TCM of Advanced Cancer --- p.27
Chapter 2.3.3 --- Treatment by TCM of Advanced Cancer --- p.28
Chapter 2.4 --- Current Evidences about the Clinical Effectiveness of TCM on Cancer Patients --- p.29
Chapter 2.5 --- The concept of Health-related Quality of Life (HRQOL) --- p.35
Chapter 2.5.1 --- The importance of HRQOL to cancer patients --- p.35
Chapter 2.5.2 --- HRQOL instruments --- p.37
Chapter 2.5.2.1 --- EORTC QLQ-C30 --- p.38
Chapter 2.5.2.2 --- SF-36 --- p.39
Chapter 2.6 --- Summary of Literature Review --- p.40
Chapter 2.7 --- The research questions --- p.41
Chapter 2.8 --- Research Hypotheses --- p.42
Chapter 2.9 --- The design of TCM protocol --- p.42
Chapter Chapter 3 --- Methodology --- p.45
Chapter 3.1 --- Introduction --- p.45
Chapter 3.2 --- Protocol --- p.45
Chapter 3.2.1 --- Study Design --- p.46
Chapter 3.2.2 --- Selection of Participants --- p.46
Chapter 3.2.2.1 --- Inclusion criteria --- p.48
Chapter 3.2.2.2 --- Exclusion criteria --- p.49
Chapter 3.2.3 --- Sample size calculation --- p.50
Chapter 3.2.4 --- Setting --- p.51
Chapter 3.2.5 --- Interventions --- p.51
Chapter 3.2.5.1 --- Treatment --- p.51
Chapter 3.2.5.2 --- Medication and dose/dosage --- p.52
Chapter 3.2.5.3 --- Treatment Assignment --- p.55
Chapter 3.2.5.4 --- Concurrent Medications --- p.56
Chapter 3.2.6 --- Procedure and Methods --- p.56
Chapter 3.2.6.1 --- Informed Consent --- p.56
Chapter 3.2.6.2 --- Documentation --- p.57
Chapter 3.2.6.3 --- Assessment Procedure --- p.57
Chapter 3.2.7 --- Outcome Measurements --- p.62
Chapter 3.2.7.1 --- Survey Questionnaire --- p.62
Chapter 3.2.7.2 --- Quality of life (QOL) instruments --- p.62
Chapter 3.2.7.3 --- Global Ratings --- p.64
Chapter 3.2.7.4 --- Physical Examination and Laboratory tests --- p.65
Chapter 3.2.8 --- Safety Considerations --- p.66
Chapter 3.2.8.1 --- Adverse Events (AE) --- p.66
Chapter 3.2.8.2 --- Serious Adverse Event (SAE) --- p.66
Chapter 3.2.8.3 --- Causality Assessment --- p.67
Chapter 3.2.9 --- Ethical consideration --- p.68
Chapter 3.2.10 --- Data Collection --- p.69
Chapter 3.3 --- Data analysis --- p.69
Chapter 3.4 --- Expected Outcomes of Study --- p.71
Chapter Chapter 4 --- Results --- p.72
Chapter 4.1 --- Study Progress --- p.72
Chapter 4.2 --- The Participants --- p.72
Chapter 4.3 --- Clinical characteristics and Socio-demographics of Participants --- p.75
Chapter 4.4 --- Main Outcome - Quality of Life --- p.78
Chapter 4.4.1 --- QLQ-C30 --- p.79
Chapter 4.4.1.1 --- Scoring and Transforming of items into scales --- p.79
Chapter 4.4.1.2 --- Changes of Individual Scale at Different Visits --- p.80
Chapter 4.4.1.3 --- Clinical significance of Scales --- p.98
Chapter 4.4.2 --- SF-36 --- p.104
Chapter 4.4.2.1 --- Scoring and Transforming of items into scales --- p.104
Chapter 4.4.2.2 --- Changes of Individual Scale at Different Visits --- p.104
Chapter 4.4.2.3 --- SF-36 Summary Scales --- p.113
Chapter 4.4.3 --- Correlation of QLQ-C30 and SF-36 --- p.115
Chapter 4.5 --- Measurement of Physical examination --- p.117
Chapter 4.5.1 --- Body Weight --- p.117
Chapter 4.6 --- Measurement of Laboratory Blood tests --- p.118
Chapter 4.6.1 --- "Comparison of CBC, RFT, LFT and LD" --- p.118
Chapter 4.6.2 --- Tumor Markers --- p.120
Chapter 4.7 --- Adverse Events and Serious Adverse Events --- p.121
Chapter 4.8 --- Global Ratings --- p.123
Chapter 4.8.1 --- Global Rating 1 - Severity of Disease --- p.123
Chapter 4.8.2 --- Global Rating 2 - Global Disease Status --- p.124
Chapter 4.8.2.1 --- Change in Global Disease Status --- p.125
Chapter 4.8.2.2 --- Agreement between RCMP and clinician --- p.125
Chapter 4.8.2.3 --- Patients' perception after treatment --- p.126
Chapter 4.9 --- Distribution of TCM patterns and Chinese herbal medicines --- p.127
Chapter 4.10 --- Survival Rate --- p.132
Chapter 4.11 --- Conclusion --- p.133
Chapter Chapter 5 --- Discussion --- p.135
Chapter 5.1 --- Conclusion on findings --- p.135
Chapter 5.2 --- Baseline profile of participants --- p.137
Chapter 5.3 --- Feasibility of TCM on advanced cancer patients --- p.139
Chapter 5.3.1 --- Recruitment of Participants --- p.139
Chapter 5.3.2 --- Compliance of participants to the study schedule --- p.140
Chapter 5.4 --- Health-related Quality of Life --- p.142
Chapter 5.5 --- Safety of TCM --- p.149
Chapter 5.6 --- Chinese medicine practitioner vs Western medicine doctor --- p.150
Chapter 5.7 --- TCM pattern differentiation and treatment --- p.151
Chapter 5.8 --- Implication of study --- p.154
Chapter 5.8.1 --- Clinical implication --- p.154
Chapter 5.8.2 --- Policy implication --- p.154
Chapter 5.9 --- Limitations of the study --- p.155
Chapter 5.10 --- Recommendations for further studies --- p.157
Chapter 5.11 --- Overall Conclusion --- p.158
Appendices --- p.160
References --- p.177
Mendes, João Pedro Pereira. "Chromatographic purification of virus particles for advanced therapy medicinal products". Master's thesis, 2017. http://hdl.handle.net/10362/24749.
Texto completoCarvalho, Marta Alexandra Bogalho Rodrigues de. "Advanced therapy medicinal products : new strategies for clinical applications of cell and gene therapy". Doctoral thesis, 2020. http://hdl.handle.net/10451/48501.
Texto completoAntunes, Brígida Isabel do Amaral Neves. "Developing an Advanced Therapy Medicinal Product (ATMP) for the treatment of GvHD". Master's thesis, 2014. http://hdl.handle.net/10362/31884.
Texto completoPinheiro, João Pedro Vicente. "Terapias Avançadas: Perspetiva Regulamentar". Master's thesis, 2019. http://hdl.handle.net/10316/88391.
Texto completoThe big news of this new therapeutic line is mainly the customization of the products to theneeds of a particular patient, striving for uniqueness and specificity.The exponential increase of scientific knowledge in the areas of biotechnology,medicine and cell biology has led to the evolution of very promising new therapies indisease prevention, control and treatment.Advanced therapy medicinal products (ATMP) have revolutionized the field of innovative therapies by offering therapeutic solutions for diseases whose treatmentes were limited or nonexistente. As such a new, innovative, complex and heterogeneous sector, strict regulatory scrutiny is of the most importance and the European Medicines Agency (EMA) has set up the Committee for Advanced Therapies (CAT), which is responsible for regulating and promoting development of this sector. Most of the entities involved in the development of this products are smal and medium enterprises (SMEs), hospitals and academic institutions, entities with limited human and financial resources, barriers that need to be overcome in order to boost this market. Some measures are underway to assist these entitites with regard to the regulatory and economic aspects, including thereduction of fees or opinion on the classification of products. Advanced therapies may in future be seen as a therapeutic pillar of health care, filling areas not covered by so-called conventional therapies, serving to increase the quality and average life expectancy of people with rare diseases hitherto inhealed.
A aumento exponencial do conhecimento científico nas áreas da biotecnologia, medicina e biologia celular conduziu à evolução de novas terapias muito promissoras na prevenção, controlo e tratamento de doenças.Os medicamentos de terapia avançada(ATMP) vieram revolucionar a área das terapias inovadoras, oferecendo soluções terapêuticas para doenças cujos tratamentos eram limitados ou inexistentes com alto grau de personalização. Por ser um setor tão recente, inovador, complexo e heterogéneo é de fulcral importância um controlo rigoroso do ponto de vista regulamentar e, com isso em vista, a Agência Europeia do Medicamento criou o Comité das Terapias Avançadas, responsável pelo regulamento e promoção do desenvolvimento deste setor. A maioria das entidades quese dedica ao desenvolvimento e comercialização destes produtos são pequenas e médias empresas (PMEs), hospitais e instituições académicas, entidades com recursos limitados a nível humano e financeiro, barreiras que necessitam de ser ultrapassadasde formaa impulsionar este mercado. Estão em curso diversas medidas que visam auxiliar estas entidades no que concerne à parte regulamentar e económica, nomeadamente redução de taxas ou opinião sobre a classificação dos produtos. As terapias avançadas poderão no futuro ser vistas como um pilar terapêutico dos cuidados de saúde, preenchendo áreas não cobertas pelas terapias ditas convencionais, servindo para aumentar a qualidade e esperança média de vida em pessoas com doenças raras ou até aí sem cura.
Costa, Joana Isabel da Conceição Curate Alves da. "Terapias avançadas: enquadramento legal e regulamentar". Master's thesis, 2016. http://hdl.handle.net/10284/5833.
Texto completoAdvanced therapy medicinal products are medicines for human use based on genes, cells or tissues. It is a group of innovative medicines, of specific nature regarding its fabric and as well its mechanism of action, that present new opportunities for treatment of diseases. These medicines are classified in four groups: gene therapy medicinal products; somatic cell therapy medicinal products; tissue engineered medicinal products and combined advanced therapy medicinal products. The need for legislative harmonisation in the european area is, to a great extent, due to the complex and specific nature of these medicines and also to remedy the existing diversity in what concerns legal requirements (each Member State has its own legal framework) and also the quality of the treatments received. The purpose of the present dissertation is to present the legal framework of the advanced therapies, addressing the main legal acts in force on the European area and also to draw its current outlook.
Stehlík, David. "Mezenchymové stromální multipotentní buňky v ortopedii: potenciace hojení kosti". Doctoral thesis, 2015. http://www.nusl.cz/ntk/nusl-349328.
Texto completoLourenço, Lúcia Machado. "Aspetos de Qualidade críticos para Farmacovigilância de Medicamentos de Terapia Génica - Células Geneticamente Modificadas". Master's thesis, 2019. http://hdl.handle.net/10316/88219.
Texto completoOs medicamentos de terapia avançada são um tema de grande destaque da atualidade no setor da Indústria Farmacêutica. O seu caráter inovador tem sido relacionado com novas abordagens terapêuticas e patologias limitantes ou fatais, para as quais, não existia no mercado nenhum tratamento eficiente.Um exemplo são as células CAR-T (Chimeric Antigen Receptor T Cells). Estas surgem como uma abordagem disruptiva no tratamento de patologias com altas taxas de recidivas. Deste tipo foram já aprovados o Yescarta (Axicabtagene ciloleucel) e o Kymriah (Tisagenlecleucel). O Tisagenlecleucel foi o primeiro medicamento com células CAR-T a receber aprovação, em 2017, da U.S. Food & Drug Administration para o tratamento de Leucemia Linfoblástica Aguda percussora de células B refratária ou com mais do que duas recidivas em crianças e jovens adultos até aos 25 anos. Em 2018, este medicamento recebeu a segunda indicação, ao ter sido indicado para adultos com linfoma de grandes células B, refratário ou com recidiva após duas ou mais linhas de terapia sistémica. De igual forma, o Tisagenlecleucel também se encontra aprovado pela Agência Europeia do Medicamento (EMA), tendo obtido aprovação em 2018 para as mesmas duas indicações acima indicadas.Os medicamentos de terapia avançada consistem em medicamentos biológicos com base em células retiradas do doente e de seguida, estas são devidamente modificadas em laboratório, sendo posteriormente difundidas no mesmo doente, de modo a potenciar a resposta imune. Devido a sua complexidade, tanto no mecanismo de ação como no método de produção, é necessário existirem, a nível regulamentar, meios que permitam a sua correta produção e utilização assim como, metodologias que assegurem a segurança após Autorização de Introdução no Mercado (AIM).Recorrendo à informação existente, regulamentar e científica, no presente trabalho são apresentados orientações e requisitos de qualidade para a produção e controlo de medicamentos de terapia avançada com base em células T geneticamente modificadas. É dado especial relevo ao medicamento Kymriah embora quase em simultâneo tenha sido também autorizado o Yescarta. São abordados requisitos de qualidade, desde a adequada recolha de células do doente, a utilização de vetores virais recombinantes para a inserção de genes nas células T obtidas e o processo de apara a sua modificação. Inclui também a avaliação de risco ambiental no contexto específico da libertação deliberada de organismos geneticamente modificados (OGM).Inclui toda a informação relevante na caracterização dos riscos, nomeadamente na enumeração e análise de medidas de gestão e mitigação de risco que devem ser aplicadas com o objetivo de alcançar a qualidade, a segurança e eficácia de longo prazo. Os riscos identificados devem ser devidamente caracterizados e controlados devido à curta duração da sua Autorização de Introdução no Mercado e ao facto de ser um medicamento biológico, com características e propriedades específicas.
Advanced therapy medicinal products (ATMP) are an important topic today for the Pharmaceutical Industry sector. Its innovative character has been related to new therapeutic approaches and limiting or fatal pathologies, for which no efficient treatment existed on the market.One ATMP example are those composed of CAR-T cells (Chimeric Antigen Receptor T Cells). These emerge as a disruptive approach in the treatment of pathologies with high relapse rates. Two CAR-T Cell ATMP, Yescarta (Axicabtagene ciloleucel) and Kymriah (Tisagencleucel), have already been approved. Tisagencleucel was the first CAR-T cell medicinal product to receive approval in 2017 from US Food & Drug Administration for the treatment of refractory B-cell percursor Acute Lymphoblastic Leukemia (ALL) with more than two relapses in children and young adults to 25 years. In 2018, this product received the second indication as it was extended to adults with refractory or relapsed B-cell Lymphoma after two or more lines of systemic therapy. Similarly, Tisagencleucel is also approved by the European Medicines Agency (EMA) in 2018.and was approved for the same indications as above.Advanced therapy medicinal products consist of biological products where T cells are taken from the patient and then appropriately modified in the laboratory and then diffuse into the same patient to enhance the immune response against the selected epitope. Due to their complexity, both in the mechanism of action and in the production method, it is necessary, at a regulatory level, to establish methodologies for its correct production and use, as well to ensure their continuous safety after marketing authorization (AIM).Using existing regulatory and scientific information, this master’s thesis presents guidelines and quality requirements for the production and control of advanced therapy medicinal products based on genetically modified autologous T-cells. Special emphasis is given to the drug Kymriah although almost simultaneously Yescarta has also been authorized. Quality requirements are addressed, from adequate collection of patient cells, their genetic modification, use of viral vectors for the transduction of the gene of interest. It also addresses the environmental risk assessment in the specific context of deliberate release of genetically modified organisms (GMOs). It covers all the relevant information on risk characterization, namely enumeration and analysis of risk management and mitigation measures that should be applied to achieve long-term quality, safety and efficacy. The identified risks must be properly characterized and controlled because of the limited experience of their post marketing surveillance and the fact that is a biological medicinal product with specific characteristics and properties.
Ewen, Andreas. "Onkologische Ergebnisse sowie objektive und subjektive Erfassung der Kehlkopffunktion nach organerhaltender lasermikrochirurgischer Resektion und adjuvanter Radio(chemo)therapie bei lokal fortgeschrittenen Larynxkarzinomen". Doctoral thesis, 2010. http://hdl.handle.net/11858/00-1735-0000-0006-AFDD-1.
Texto completo